作者
Aurelien Amiot, Vida Setakhr, Philippe Seksik, Mathieu Allez, Xavier Treton, Martine De Vos, David Laharie, Jean-Frederic Colombel, Vered Abitbol, Jean Marie Reimund, Jacques Moreau, Michel Veyrac, Bernard Flourié, Jacques Cosnes, Marc Lemann, Yoram Bouhnik
发表日期
2014/9/1
期刊
Official journal of the American College of Gastroenterology| ACG
卷号
109
期号
9
页码范围
1443-1449
出版商
LWW
简介
OBJECTIVES:
Although anti-tumor necrosis factor (TNF) therapy is the treatment of choice for perianal fistulizing Crohn's disease (CD), the efficacy and safety of anti-TNF therapy in enterocutaneous fistula (ECF) remains unclear.
METHODS:
Between January 2008 and December 2009, we retrospectively reviewed the outcomes of all CD patients with ECF (excluding perianal fistula) treated with anti-TNF therapy followed up in Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) centers. ECF closure and tolerance of anti-TNF therapy were studied using univariate and multivariate analyses.
RESULTS:
Forty-eight patients (twenty-six women; median age 34.6 (interquartile range= 25.0–45.5) years) were included in this study. The median follow-up period was 3.0 (2.0–6.6) years. The fistula was located in the small bowel (n= 38), duodenum (n= 1), and colon (n= 9). The fistula has been …
学术搜索中的文章
A Amiot, V Setakhr, P Seksik, M Allez, X Treton… - Official journal of the American College of …, 2014